Associated tags: Cancer, Health, Oncology, TME, Therapy, Tumor microenvironment, Research, Biotechnology, Pharmaceutical, Neoplasm, Science, Clinical Trials, DDR1, Parthenon, Pharmaceutical industry, MD, General Health, Patient
Retrieved on:
Monday, November 13, 2023
Research,
Clinical Trials,
Biotechnology,
Health,
Pharmaceutical,
General Health,
Other Science,
Science,
Oncology,
RAPT,
Associate,
Therapy,
Haas School of Business,
University of California, Berkeley,
Hospital,
Patient,
Cancer,
Tumor microenvironment,
Pembrolizumab,
TME,
University,
Drug discovery,
Growth,
Medical college,
Neoplasm,
Triple accreditation,
Critical Care Medicine (journal),
Pharmaceutical industry,
Anesthesiology The company also announced that the first patient has been dosed with PRTH-101 in the Phase 1b multiple-ascending dose trial cohort for the treatment of patients with immune-excluded solid tumors.
Key Points:
- The company also announced that the first patient has been dosed with PRTH-101 in the Phase 1b multiple-ascending dose trial cohort for the treatment of patients with immune-excluded solid tumors.
- The Phase 1b clinical trial will evaluate PRTH-101 treatment across three different dose levels in combination with KEYTRUDA® (pembrolizumab).
- The outcome of the trial will guide the company in determining the recommended Phase 2 dose for PRTH-101.
- Cancer patients suffering from immune excluded tumors remain in need of effective therapies,” said Wendye Robbins, M.D., President and Chief Executive Officer of Incendia.
Oncology,
Health,
Clinical Trials,
General Health,
Pharmaceutical,
Biotechnology,
Congress,
Cancer,
TME,
Tumor microenvironment,
DDR1,
ESMO,
Therapy,
Mesenchyme,
European Society for Medical Oncology,
Neoplasm,
Translational medicine,
Pharmaceutical industry,
Medical imaging Incendia Therapeutics , formerly Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will have two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2023, to be held in Madrid, Spain October 20-24, 2023.
Key Points:
- Incendia Therapeutics , formerly Parthenon Therapeutics, a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that it will have two poster presentations at the European Society for Medical Oncology (ESMO) Congress 2023, to be held in Madrid, Spain October 20-24, 2023.
- A high proportion of tumor cells (median of 0.76) expressed DDR1 across all epithelial tumor types.
- DDR1 expression was uniformly low in mesenchymal tumors (median of 9 cells/mm2) compared to epithelial tumors (median of 2803 cells/mm2).
- The third part (Ph1c) consists of dose expansion in disease-directed cohorts to assess the anti-tumor efficacy of PRTH-101 monotherapy and/or combination therapy.
Research,
Clinical Trials,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Science,
Oncology,
Neoplasm,
DDR1,
Parthenon,
JITC,
Journal,
MD,
University,
TME,
Mab,
Collagen,
ECM,
Therapy,
Immunotherapy,
George Washington University,
Tumor microenvironment,
Breast cancer,
Pharmaceutical industry,
Cancer Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from a collaboration between Parthenon Therapeutics, The University of Texas Health Center at Houston (UTHealth Houston) and George Washington University, demonstrating that PRTH-101 potently inhibits the adhesion of collagen receptor discoid in domain receptor-1 (DDR1)-expressing cancer cells to collagen substrates and DDR1 autophosphorylation induced by collagen.
Key Points:
- Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from a collaboration between Parthenon Therapeutics, The University of Texas Health Center at Houston (UTHealth Houston) and George Washington University, demonstrating that PRTH-101 potently inhibits the adhesion of collagen receptor discoid in domain receptor-1 (DDR1)-expressing cancer cells to collagen substrates and DDR1 autophosphorylation induced by collagen.
- The article entitled, “A highly selective humanized DDR1 mAb reverses immune exclusion by disrupting collagen fiber alignment in breast cancer,” describes the humanization of PRTH-101 and the mechanism by which the drug candidate binds to its target to inhibit DDR1.
- The publication is now available online on the JITC website .
- “This study reinforces the development of PRTH-101 as a cancer therapeutic, and also sheds light on a new therapeutic strategy to modulate collagen alignment in the tumor ECM for enhancing antitumor immunity.”
Science,
Biotechnology,
Research,
Pharmaceutical,
Oncology,
General Health,
Health,
Other Health,
Paper,
Neoplasm,
JITC,
Therapy,
Immunotherapy,
Journal,
MD,
Tumor microenvironment,
Parthenon,
TME,
Vaccine,
Cancer Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from an international panel of cancer experts convened to provide an initial consensus on the role of immune exclusion in cancer.
Key Points:
- Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the Journal for ImmunoTherapy of Cancer (JITC) has published results from an international panel of cancer experts convened to provide an initial consensus on the role of immune exclusion in cancer.
- The article “Developing a Definition of Immune Exclusion in Cancer: Results of a Modified Delphi Workshop,” identifies key characteristics of and issues relevant to the role immune exclusion plays in resistance to checkpoint therapy and is now available online.
- “Immune exclusion until now has not had a well-defined profile, but we know it exists across multiple tumor types,” said J. Paul Eder, MD, Chief Medical Officer of Parthenon Therapeutics.
- “In collaboration with academic leaders, Parthenon is pioneering how to recognize and define immune exclusion in cancer and understand the mechanisms underlying it.
Oncology,
Health,
Clinical Trials,
Research,
Science,
Pharmaceutical,
Biotechnology,
DDR1,
Cancer,
Neoplasm,
FDA,
Therapy,
MD,
Tumor microenvironment,
Patient,
Parthenon,
TME,
Medical imaging Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the first patient has been dosed with PRTH-101 in a Phase 1, first-in-human clinical trial for patients with immune-excluded solid tumors.
Key Points:
- Parthenon Therapeutics , a precision oncology company discovering and developing a novel class of therapies that reprogram the tumor microenvironment (TME), today announced that the first patient has been dosed with PRTH-101 in a Phase 1, first-in-human clinical trial for patients with immune-excluded solid tumors.
- PRTH-101 is a first-in-class Discoidin Domain Receptor 1 (DDR1) antagonist monoclonal antibody that is expressed at very high levels in solid tumors with low levels of T cell infiltration.
- PRTH-101 is the first development candidate from Parthenon’s broad TME-focused pipeline to enter clinical development.
- PRTH-101 uniquely targets DDR1 and has demonstrated, in preclinical models, anti-tumor activity as a single agent and in combination with an anti-PD-1 checkpoint inhibitor.
Oncology,
Health,
FDA,
Clinical Trials,
Research,
Science,
AACR,
Prevalence,
DDR1,
Clinical trial,
Clinical research,
Cancer,
Multimedia,
Lung cancer,
Doctor of Philosophy,
Parthenon,
Incidence,
Sarcoma,
Translational medicine,
Patient,
Colorectal cancer,
TME,
Immunohistochemistry,
American Association for Cancer Research,
Therapy,
Ovarian cancer,
Tumor microenvironment,
Pharmaceutical industry,
Vaccine,
MD The data further support Parthenon’s planned Phase 1 clinical trial of lead candidate PRTH-101, a novel Discoidin Domain Receptor (DDR1) inhibitor which targets DDR1-directed collagen barriers in immune excluded tumors.
Key Points:
- The data further support Parthenon’s planned Phase 1 clinical trial of lead candidate PRTH-101, a novel Discoidin Domain Receptor (DDR1) inhibitor which targets DDR1-directed collagen barriers in immune excluded tumors.
- However, most patients with solid tumors lack immune cells in physical proximity to tumor cells.
- This can be due to collagen barriers that prevent immune cells from reaching tumor cells in immune excluded tumors.
- The poster detailing these findings - #2108 - will be presented at the American Association of Cancer Research (AACR) Annual Meeting on Monday, April 17, 2023.
